PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease Reportschronic hepatitis b
MeSH D019694 - chronic hepatitis b
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D006509:Hepatitis b
$
Success rate
D006521:Chronic hepatitis
0 Companies
0 Drugs
Success rate
D019694: 
Chronic hepatitis b
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaEmtricitabine, Tenofovir disoproxil, Efavirenz Efavirenz, Emtricitabine, Tenofovir Disoproxil  2018-11-09   
Emtricitabine, Tenofovir disoproxil Emtricitabine Tenofovir Disoproxil  2017-06-08   
Entecavir Entecavir  2014-08-26   
Lamivudine Lamivudine Teva  2009-10-23   
Tenofovir disoproxil Tenofovir Disoproxil  2015-03-18   
MylanTenofovir disoproxil, Lamivudine Cimduo  2018-02-28   
Emtricitabine, Tenofovir disoproxil, Efavirenz Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan  2017-09-05   
Emtricitabine, Tenofovir disoproxil Emtricitabine Tenofovir Disoproxil  2018-04-09   
Emtricitabine, Tenofovir disoproxil Emtricitabine/Tenofovir disoproxil Mylan  2016-12-16   
Entecavir Entecavir Mylan  2017-09-18   
Tenofovir disoproxil, Efavirenz, Lamivudine Symfi  2018-03-22   
Tenofovir disoproxil, Efavirenz, Lamivudine Symfi Lo  2018-02-05   
Tenofovir disoproxil Tenofovir Disoproxil  2018-11-27   
Tenofovir disoproxil Tenofovir disoproxil Mylan  2016-12-08   
Johnson & JohnsonTenofovir alafenamide, Cobicistat, Emtricitabine, Darunavir Symtuza 2022-02-02 2018-07-17   
GSKLamivudine Zeffix  1999-07-29   
RocheRibavirin, Peginterferon alfa-2a Pegasys Copegus  2004-06-04   
CiplaEmtricitabine, Tenofovir disoproxil, Efavirenz Efavirenz, Emtricitabine, Tenofovir Disoproxil  2019-06-03   
Emtricitabine, Tenofovir disoproxil Emtricitabine Tenofovir Disoproxil  2021-04-02   
Entecavir Entecavir  2016-12-06   
Tenofovir disoproxil Tenofovir Disoproxil  2018-01-26   
Chartwell PharmaceuticalsEmtricitabine, Tenofovir disoproxil Emtricitabine Tenofovir Disoproxil  2021-06-04   
Tenofovir disoproxil Tenofovir Disoproxil  2018-07-26   
Entecavir Entecavir  2017-05-11   
Tenofovir disoproxil, Lamivudine Temixys  2018-11-16   
NovartisTelbivudine Sebivo  2007-04-24   
Telbivudine Tyzeka 2023-09-11 2006-10-25   
Merck & CoDoravirine, Tenofovir disoproxil, Lamivudine Delstrigo 2031-10-07 2018-08-30 $233 M Q3/23-Q3/24 
Interferon alfa-2b Intron A  1986-06-04   
Interferon alfa-2b IntronA  2000-03-09   
Interferon alfa-2b Viraferon  2000-03-09   
Aurobindo PharmaEmtricitabine, Tenofovir disoproxil, Efavirenz Efavirenz, Emtricitabine, Tenofovir Disoproxil  2018-09-04   
Tenofovir disoproxil, Efavirenz, Lamivudine Efavirenz, Lamivudine Tenofovir Disoproxil  2018-08-15   
Emtricitabine, Tenofovir disoproxil Emtricitabine Tenofovir Disoproxil  2018-01-26   
Entecavir Entecavir  2015-08-26   
Tenofovir disoproxil, Lamivudine Lamivudine Tenofovir Disoproxil  2018-05-15   
Tenofovir disoproxil Tenofovir Disoproxil  2018-01-26   
1
2
3
4
>
Clinical Trials
Historical Success Rate
Phase 1
55%
21/38
Phase 2
65%
30/46
Phase 3
70%
28/40
Approved: 12Overall Success rate: 25%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Mylan
1
2
3
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use